Analyst on what Biogen's Alzheimer's drug means for the company

SAVA DCF Analysis .. SCPH SoaringПодробнее

Biogen Alzheimer's drug may be 'first effort of a clear win': AnalystПодробнее

Biogen Analyst Sees No Clear Growth Driver to Replace Alzheimer's DrugПодробнее

Biogen Alzheimer's Drug: Doctors 'won't come out of the gates prescribing' this: AnalystПодробнее

Biogen CEO on FDA approval for its Alzheimer's drugПодробнее

Analyzing the clinical data for Aduhelm, Biogen's controversial Alzheimer's drugПодробнее

What Biogen halted its Alzheimer's drug trial means for biotech investorsПодробнее

This analyst breaks down the bull case for Biogen's Alzheimer's drugПодробнее

Alzheimer's drug will lead to some societal decisions: AnalystПодробнее

Why this analyst remains a 'skeptic' on Biogen's new Alzheimer's drugПодробнее

Analyst on what Biogen's Alzheimer's drug means for the companyПодробнее

Biogen's Alzheimer’s drug could generate ‘$8 billion in peak sales’: AnalystПодробнее

Biogen shares spike after FDA approves Alzheimer's drugПодробнее

What’s The Controversy Behind Biogen’s Alzheimer’s Drug?Подробнее

Biogen soars on promising results from Alzheimer's drug trialПодробнее

Analyst: It's unclear whether Biogen's new Alzheimer's drug will get approvedПодробнее

Biogen to seek FDA approval for Alzheimer's drug AducanumabПодробнее

FDA approves Biogen Alzheimer's treatmentПодробнее

FDA approves Biogen's Alzheimer's drugПодробнее

Alzheimer's drug decision day: FDA to decide on Biogen and Eisai treatmentsПодробнее

Biogen shares drop as big clinics say they won't administer controversial Alzheimer's drugПодробнее

Cramer: Biogen's Alzheimer's treatment would be 'the biggest drug ever'Подробнее